litlas
Log inCreate account

Stephen Falk

Active 2000–2024

63
Papers
22,022
Citations
49
h-index
61
i10-index

Citations

Citations per year for Stephen Falk1939: 1 citations2001: 4 citations2002: 10 citations2003: 13 citations2004: 9 citations2005: 8 citations2006: 18 citations2007: 30 citations2008: 45 citations2009: 40 citations2010: 73 citations2011: 87 citations2012: 63 citations2013: 115 citations2014: 140 citations2015: 139 citations2016: 147 citations2017: 192 citations2018: 160 citations2019: 731 citations2020: 832 citations2021: 738 citations2022: 557 citations2023: 412 citations2024: 682 citations2025: 252 citations2026: 8 citations1940–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,548 citing papers, 19% of this breakdownChina: 860 citing papers, 10.6% of this breakdownUnited Kingdom: 730 citing papers, 9% of this breakdownGermany: 580 citing papers, 7.1% of this breakdownItaly: 503 citing papers, 6.2% of this breakdownJapan: 462 citing papers, 5.7% of this breakdownNetherlands: 388 citing papers, 4.8% of this breakdownFrance: 346 citing papers, 4.2% of this breakdownSouth Korea: 226 citing papers, 2.8% of this breakdownSpain: 220 citing papers, 2.7% of this breakdownCanada: 207 citing papers, 2.5% of this breakdownAustralia: 186 citing papers, 2.3% of this breakdown
0%19%Other 23.1%

Institutions

Fields

  • Medicine88.4%
  • Biochemistry, Genetics and Molecular Biology7%
  • Immunology and Microbiology1.7%
  • Materials Science0.7%
  • Engineering0.4%
  • Health Professions0.3%
  • Other1.5%

Topics

  • Gastric Cancer Management and Outcomes9.6%
  • Pancreatic and Hepatic Oncology Research9.1%
  • Cholangiocarcinoma and Gallbladder Cancer Studies7.1%
  • Esophageal Cancer Research and Treatment6.6%
  • Colorectal Cancer Treatments and Studies3.5%
  • Gallbladder and Bile Duct Disorders3.1%
  • Other61%

Coauthors

All papers

Open in search
  1. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

    Authors: David Cunningham, William Allum, Sally Stenning, J N Thompson, Cornelis J.�H. van de Velde, M. Nicolson, J.H. Scarffe, F. Lofts, Stephen Falk, Timothy Iveson, David B. Smith, Ruth E. Langley, Monica Verma, Simon Weeden, Yu Jo Chua - New England Journal of Medicine 2006 cited by 6,362

  2. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    Authors: John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh, Eftychia Eirini Psarelli, Juan W. Valle, Christopher Halloran, Olusola Olusesan Faluyi, Derek O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R. Izbicki, Gary Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W. Büchler - The Lancet 2017 cited by 1,928

  3. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

    Authors: John N Primrose, Richard Fox, Daniel H. Palmer, Hassan Malik, Rajendra Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones, Harpreet Wasan, Paul J. Ross, Lucy Wall, Jonathan Wadsley, JEFF EVANS, Deborah Stocken, Raaj Praseedom, Yuk Ting, Brian R Davidson, John P. Neoptolemos, Timothy Iveson, James Raftery, Shihua Zhu, David Cunningham, O. James Garden, Clive Stubbs, Juan W. Valle, John Bridgewater, John Primrose, RP Fox, Helen Morement, Oscar S.H. Chan, C. Rees, Ma Yt, Tamas Hickish, Stephen Falk, Meg Finch-Jones, Ian Pope, Pippa Corrie, Tom Crosby, S. Sothi, K Sharkland, Douglas Adamson, Lucy Wall, JEFF EVANS, John Dent, U. Hombaiah, Chinenye Iwuji, Alan Anthoney, John Bridgewater, David Cunningham, Roopinder Gillmore, Paul J. Ross, S. Slater, Harpreet Wasan, Jill Waters, Juan W. Valle, Daniel H. Palmer, Hafiz Malik, John P. Neoptolemos, Olusola Olusesan Faluyi, Kate Sumpter, U. Dernedde, S Maduhusudan, G. Cogill, Caroline Archer, Timothy Iveson, Jonathan Wadsley, Suzanne Darby, Mike Peterson, AA Mukhtar, JG Thorpe, Adrian C Bateman, D. Tsang, S. Cummins, L. Nolan, Éric Beaumont, Rajendra Prasad, D. Mirza, Deborah Stocken, Raaj Praseedom, Brian R Davidson, James Raftery, Shihua Zhu, James Garden, C Stubbs, Fareeda Y. Coxon - The Lancet Oncology 2019 cited by 1,228

  4. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

    Authors: Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Timothy Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David J. Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle - The Lancet Oncology 2021 cited by 749

  5. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

    Authors: John Bridgewater, Peter Fletcher, Daniel H. Palmer, Hassan Z. Malik, Raj Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones, Harpreet Wasan, Paul Ross, Lucy Wall, Jonathan Wadsley, Thomas R. Evans, Deborah Stocken, Clive Stubbs, Raaj Praseedom, Yuk Ting Ma, Brian Davidson, John Neoptolemos, Tim Iveson, David Cunningham, O. James Garden, Juan W. Valle, John Primrose, on behalf of the BILCAP study group - Journal of Clinical Oncology 2022 cited by 189

  6. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

    Authors: Gary Middleton, Paul Silcocks, Trevor F. Cox, Juan W. Valle, Jonathan Wadsley, David Propper, Fareeda Y. Coxon, Paul J. Ross, Srinivasan Madhusudan, Tom Roques, David Cunningham, Stephen Falk, Nick Wadd, Mark Harrison, Pippa Corrie, Timothy Iveson, Angus Robinson, Karen McAdam, Martin Eatock, JEFF EVANS, Caroline Archer, Tamas Hickish, Angel Garcia-Alonso, M. Nicolson, William P. Steward, Alan Anthoney, William Greenhalf, Victoria Shaw, Eithne Costello, Dean J. Naisbitt, Charlotte Rawcliffe, Gemma Nanson, John P. Neoptolemos - The Lancet Oncology 2014 cited by 374

  7. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

    Authors: John V. Reynolds, Shaun R. Preston, Brian Patrick O’Neill, Maeve A. Lowery, Lene Bæksgaard, T. Crosby, Moya Cunningham, Sinéad Cuffe, Gareth Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, George B. Hanna, Frederick R. Bartlett, Alberto Alvarez‐Iglesias, Michael Patrick Achiam, Magnus Nilsson, Guillaume Piessen, Narayanasamy Ravi, Dermot O’Toole, Ciarán Johnston, Raymond S McDermott, Richard Turkington, Shajahan Wahed, Sharmila Sothi, Hugo Ford, Martin Wadley, Derek G. Power, Somnath Mukherjee, Carys Morgan, Simon L. Parsons, Neel Bhuva, Sorcha Campbell, Liam Grogan, Greg Leonard, Andrew Bateman, Catherine Mitchell, Séamus O’Reilly, Eibhlin Mulroe, Olivia McLoughlin, Anna Shevlin, Aoife M. Shannon, Jacinta Marron, Marc Nolan, Grace Burch, Michelle Costello, Daniel E. Griffiths, Kelly Cozens, Emma Foley, Claire L. Donohoe, Catherine O’Farrell, Jennifer E. Moore, Jacintha O’Sullivan - ˜The œLancet. Gastroenterology & hepatology 2023 cited by 173

  8. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

    Authors: Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson, Paula Ghaneh, Christopher Halloran, Daniel H. Palmer, Fiona Campbell, Juan W. Valle, Olusola Olusesan Faluyi, Derek O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R. Izbicki, Gary Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Markus M. Lerch, Julia Mayerle, Christine Tjaden, Oliver Strobel, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos, for the European Study Group for Pancreatic Cancer - JAMA Surgery 2019 cited by 273

  9. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

    Authors: Hugo Ford, Andrea Marshall, John Bridgewater, Tobias Janowitz, Fareeda Y. Coxon, Jonathan Wadsley, Wasat Mansoor, D. Fyfe, Srinivasan Madhusudan, Gary Middleton, Daniel Swinson, Stephen Falk, Ian Chau, David Cunningham, Paula Kareclas, Natalie Cook, Jane Blazeby, Janet Dunn - The Lancet Oncology 2013 cited by 604

  10. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

    Authors: Simron Singh, Daniel M. Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Pamela L. Kunz, Beth Chasen, Jaume Capdevila, Salvatore Tafuto, Do‐Youn Oh, Changhoon Yoo, Stephen Falk, Þorvarður R. Hálfdánarson, Ilya Folitar, Yufen Zhang, Paola Santoro, Paola Aimone, Wouter W. de Herder, Diego Ferone - Journal of Clinical Oncology 2024 cited by 45

  11. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

    Authors: Susan Dutton, David Ferry, Jane Blazeby, Haider Abbas, Åsa Dahle-Smith, Wasat Mansoor, Joyce Thompson, Mark Harrison, Anirban Chatterjee, Stephen Falk, Angel Garcia-Alonso, D. Fyfe, Richard Hubner, Tina Gamble, Lynnda Peachey, Mina Davoudianfar, Sarah Pearson, Patrick Julier, Janusz Jankowski, Rachel Kerr, Russell Petty - The Lancet Oncology 2014 cited by 330

  12. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

    Authors: Peter S Hall, Daniel Swinson, David A. Cairns, Justin S. Waters, Russell Petty, Christine Allmark, Sharon Ruddock, Stephen Falk, Jonathan Wadsley, Rajarshi Roy, Tania Tillett, J. J. Nicoll, Sebastian Cummins, Joseph Mano, Simon Grumett, Zuzana Stokes, Konstantinos-Velios Kamposioras, Anirban Chatterjee, Angel Garcia, Tom Waddell, Kamalnayan Guptal, Nick Maisey, Mohammed Q. Khan, Jo Dent, Simon Lord, Ann Crossley, Eszter Katona, Helen Marshall, Heike I. Grabsch, Galina Velikova, Pei Loo Ow, Catherine Handforth, Helen Howard, Michel Seymour, GO2 Trial Investigators, Eleanor James, Sue Cheeseman, Tom Roques, Nick Reed, Charles Candish, D. Fyfe, Kim Last, Richard Ellis, Lesley Samuel, Rebecca Herbertson, Louise Medley, Kinnari Patel, David Sherriff, Angus Robinson, Pavel Bezecny, Dunca Wilkins, Adam McGeoch, D. Propper, Olwyn Williams, Serena Hilman, Sherif Raouf, Claire Hobbs, J.A. Parkinson, Nick Wadd, W Saku, Victori Kunene, C Askill, Arshad Jamil, Emma Cattell, Lauren Gorf, Vallipuram Vigneswaran, Erica Beaumont, Syed M. Zubair, Elin Jones, Nicholas Reed, Alaaeldin Shablak, George Bozas, Sheela Rao, Michael Bennet, Joanne Askey, Gareth Griffiths, Sally Clive, Vanessa Potter, Jean Roger Le Gall, Chris Twelves, M.R. Sydes, Juan W. Valle, Jo Webster, Marc Jones, Fiona Collinson, Julia Brown, Louise Brook - JAMA Oncology 2021 cited by 191

  13. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

    Authors: David Cunningham, Ian Chau, Deborah Stocken, Juan W. Valle, David B. Smith, William P. Steward, Peter Harper, Janet Dunn, Catrin Tudur Smith, Julia West, Stephen Falk, A. Crellin, F. Adab, Joyce Thompson, Pauline Leonard, J. Ostrowski, Martin Eatock, Werner Scheithauer, Richard Herrmann, John P. Neoptolemos - Journal of Clinical Oncology 2009 cited by 818

  14. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

    Authors: Tom Waddell, Ian Chau, David Cunningham, David González de Castro, Alicia Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley, David Ferry, Wasat Mansoor, Tom Crosby, Fareeda Y. Coxon, David A. Smith, Justin S. Waters, Timothy Iveson, Stephen Falk, Sarah Slater, Clare Peckitt, Yolanda Barbáchano - The Lancet Oncology 2013 cited by 728

  15. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

    Authors: John Bridgewater, S. Pugh, Tom Maishman, Zina Eminton, J. M. MELLOR, Amy Whitehead, Louise Stanton, M Radford, Andrea Corkhill, Gareth Griffiths, Stephen Falk, Juan W. Valle, Derek O’Reilly, Ajith K. Siriwardena, Joanne Hornbuckle, Myrddin Rees, Timothy Iveson, Tamas Hickish, O. James Garden, David Cunningham, Tim Maughan, John N Primrose, Alaaeldin Shablack, Ann O’Callaghan, Anne Marie Moody, Alex Allen, A. Brewster, Alison Brown, Astrid Mayer, Brian R Davidson, Chan Ton, Charles Wilson, C. Lowdell, Charlotte Rees, Christopher Baughan, Clare Barlow, Colin Purcell, David Smith, David Tsang, Ewan Brown, Georgina Walker, Hassan Malik, Iain Cameron, Luke Nolan, Marcia Hall, Marjorie Tomlinson, Mark Hill, Mark Peterson, Meg Finch-Jones, Nagappan Kumar, N D Karanjia, Nasim Ali, Nigel Heaton, Nua Chan Ton, Paul J. Ross, Raaj Praseedom, Robert Thomas, Sally Clive, Sarah Slater, Sarah Smith, Satvinder Mudan, Satya Bhattacharya, Sharadah Essapen, Sherif Raouf, Stephen W. Fenwick, Susan Cleator, Tom Diamond, Vanessa Potter - The Lancet Oncology 2020 cited by 239

  16. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

    Authors: R.D. James, Rob Glynne‐Jones, Helen Meadows, David Cunningham, Arthur Sun Myint, Mark Saunders, Tim Maughan, Alec McDonald, Sharadah Essapen, Martin Leslie, Stephen Falk, Charles B. Wilson, Simon Gollins, Rubina Begum, Jonathan A. Ledermann, Latha Kadalayil, David Sebag‐Montefiore - The Lancet Oncology 2013 cited by 733

  17. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

    Authors: Somnath Mukherjee, Chris Hurt, John Bridgewater, Stephen Falk, Sebastian Cummins, Harpreet Wasan, Tom Crosby, Catherine Jephcott, Rajarshi Roy, Ganesh Radhakrishna, Alec McDonald, Ruby Ray, George Joseph, John Staffurth, Ross A. Abrams, Gareth Griffiths, Tim Maughan - The Lancet Oncology 2013 cited by 354

  18. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

    Authors: John Primrose, Stephen Falk, Meg Finch-Jones, Juan W. Valle, Derek O’Reilly, Ajith K. Siriwardena, Joanne Hornbuckle, Mark Peterson, Myrddin Rees, Timothy Iveson, Tamas Hickish, Rachel Butler, Louise Stanton, Elizabeth Dixon, Louisa Little, Megan Bowers, S. Pugh, O. James Garden, David Cunningham, Tim Maughan, John Bridgewater - The Lancet Oncology 2014 cited by 433

  19. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

    Authors: Michel Seymour, Sarah Brown, Gary Middleton, Tim Maughan, Susan D. Richman, Stephen J. Gwyther, Catherine Lowe, Jennifer Seligmann, Jonathan Wadsley, Nick Maisey, Ian Chau, Mark Hill, L. Dawson, Stephen Falk, Ann O’Callaghan, Kim Benstead, Philip Chambers, Alfred Oliver, Helen Marshall, Vicky Napp, Philip Quirke - The Lancet Oncology 2013 cited by 392

  20. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    Authors: Harpreet Wasan, Peter Gibbs, Navesh Sharma, Julien Taı̈eb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S. Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins, David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, F. Lofts, Sarah Lowndes, Astrid Mayer, Matthew S. Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, R. Muirhead, Andreas Polychronis, Colin Purcell, Paul J. Ross, Ricky A. Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael D. Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi‐Jen Chen, P. Chevallier, Michael Chuong, Stephen Clarke, Andrew L. Coveler, M Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas W. Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Melita A. Gordon, Kate Gregory, Seza A. Güleç, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew P. Holtzman, Richard Isaacs, Christopher Jackson and 156 more - The Lancet Oncology 2017 cited by 398

  21. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial

    Authors: Lisa Lowry, Paul Smith, Wendi Qian, Stephen Falk, Kim Benstead, Tim Illidge, David C. Linch, Martin Robinson, Andrew Jack, Peter Hoskin - Radiotherapy and Oncology 2011 cited by 386

  22. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

    Authors: David Cunningham, Sally Stenning, Elizabeth Smyth, Alicia Okines, William Allum, Sam Rowley, Laura Stevenson, Heike I. Grabsch, Derek Alderson, T. Crosby, S M Griffin, Wasat Mansoor, Fareeda Y. Coxon, Stephen Falk, Suzanne Darby, Kate Sumpter, Jane Blazeby, Ruth E. Langley - The Lancet Oncology 2017 cited by 288

  23. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

    Authors: Timothy Iveson, Rachel Kerr, Mark Saunders, Jim Cassidy, Niels Henrik Holländer, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Claire Scudder, Kathleen Boyd, Andrew Briggs, Ashita Waterston, Louise Medley, Charles B. Wilson, Richard Ellis, Sharadah Essapen, A.S. Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul - The Lancet Oncology 2018 cited by 188

  24. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

    Authors: T. Crosby, Chris Hurt, Stephen Falk, Simon Gollins, Somnath Mukherjee, John Staffurth, Ruby Ray, Nadim Bashir, John Bridgewater, J I Geh, David Cunningham, Jane Blazeby, Rajarshi Roy, Tim Maughan, Gareth Griffiths - The Lancet Oncology 2013 cited by 381